Literature DB >> 9591658

Sensitivity to voltage-independent inhibition determined by pore-lining region of the acetylcholine receptor.

M M Francis1, K I Choi, B A Horenstein, R L Papke.   

Abstract

Some noncompetitive inhibitors (e.g., ganglionic blockers) exhibit selectivity for the inhibition of neuronal nicotinic acetylcholine receptors (nAChRs). This study characterizes the mechanism of selective long-term inhibition of neuronal and muscle-neuronal chimeric nAChRs by bis(2,2,6,6-tetramethyl-4-piperidinyl) sebacate (bis-TMP-10 or BTMPS), a bifunctional form of the potent ganglionic blocker tetramethylpiperidine. Long-term inhibition of neuronal nAChRs by bis-TMP-10 has been previously demonstrated to arise, at least in part, from the binding of the bis compound to neuronal beta-subunits. In this study, long-term inhibition is demonstrated to be dependent upon the presence of sequence element(s) within the pore-lining second transmembrane domain (tm2) of neuronal beta-subunits; however, the inhibitor binding site itself does not appear to be contained within the segment of the channel pore influenced by the membrane electric field. Specifically, our results imply that bis-TMP-10 interacts with an activation-sensitive element, the availability of which may be regulated by a sequence in the tm2 domain. Furthermore, we demonstrate a compound length requirement for long-term inhibition that would be consistent with binding to multiple sites located on the extracellular portion of the receptor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9591658      PMCID: PMC1299574          DOI: 10.1016/S0006-3495(98)77940-8

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  39 in total

1.  1:2:2:6:6-Pentamethylpiperidine: a new hypotensive drug.

Authors:  G E LEE; W R WRAGG; S J CORNE; N D EDGE; H W READING
Journal:  Nature       Date:  1958-06-21       Impact factor: 49.962

2.  "Orphan" alpha6 nicotinic AChR subunit can form a functional heteromeric acetylcholine receptor.

Authors:  V Gerzanich; A Kuryatov; R Anand; J Lindstrom
Journal:  Mol Pharmacol       Date:  1997-02       Impact factor: 4.436

3.  Local anaesthetics transiently block currents through single acetylcholine-receptor channels.

Authors:  E Neher; J H Steinbach
Journal:  J Physiol       Date:  1978-04       Impact factor: 5.182

4.  Structure of the high-affinity binding site for noncompetitive blockers of the acetylcholine receptor: serine-262 of the delta subunit is labeled by [3H]chlorpromazine.

Authors:  J Giraudat; M Dennis; T Heidmann; J Y Chang; J P Changeux
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

5.  The handedness of the subunit arrangement of the nicotinic acetylcholine receptor from Torpedo californica.

Authors:  J Machold; C Weise; Y Utkin; V Tsetlin; F Hucho
Journal:  Eur J Biochem       Date:  1995-12-01

6.  Electron microscopy of complexes of isolated acetylcholine receptor, biotinyl-toxin, and avidin.

Authors:  E Holtzman; D Wise; J Wall; A Karlin
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

7.  Determinants of nicotinic receptor gating in natural and unnatural side chain structures at the M2 9' position.

Authors:  P C Kearney; H Zhang; W Zhong; D A Dougherty; H A Lester
Journal:  Neuron       Date:  1996-12       Impact factor: 17.173

8.  The arrangement of the subunits of the acetylcholine receptor of Torpedo californica.

Authors:  A Karlin; E Holtzman; N Yodh; P Lobel; J Wall; J Hainfeld
Journal:  J Biol Chem       Date:  1983-06-10       Impact factor: 5.157

9.  Studies on the mechanism of action of acetylcholine antagonists on rat parasympathetic ganglion cells.

Authors:  P Ascher; W A Large; H P Rang
Journal:  J Physiol       Date:  1979-10       Impact factor: 5.182

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  7 in total

1.  Multiple modes of α7 nAChR noncompetitive antagonism of control agonist-evoked and allosterically enhanced currents.

Authors:  Can Peng; Matthew R Kimbrell; Chengju Tian; Thomas F Pack; Peter A Crooks; E Kim Fifer; Roger L Papke
Journal:  Mol Pharmacol       Date:  2013-07-09       Impact factor: 4.436

2.  Extending the analysis of nicotinic receptor antagonists with the study of alpha6 nicotinic receptor subunit chimeras.

Authors:  Roger L Papke; Linda P Dwoskin; Peter A Crooks; Guangrong Zheng; Zhenfa Zhang; J Michael McIntosh; Clare Stokes
Journal:  Neuropharmacology       Date:  2008-03-28       Impact factor: 5.250

3.  Determinants of phencyclidine potency on the nicotinic acetylcholine receptors from muscle and electric organ.

Authors:  V A Eterović; R Lu; A E Eakin; A D Rodríguez; P A Ferchmin
Journal:  Cell Mol Neurobiol       Date:  1999-12       Impact factor: 5.046

4.  Antagonist activities of mecamylamine and nicotine show reciprocal dependence on beta subunit sequence in the second transmembrane domain.

Authors:  J C Webster; M M Francis; J K Porter; G Robinson; C Stokes; B Horenstein; R L Papke
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

5.  Persistent activation of α7 nicotinic ACh receptors associated with stable induction of different desensitized states.

Authors:  Roger L Papke; Clare Stokes; M Imad Damaj; Ganesh A Thakur; Khan Manther; Millet Treinin; Deniz Bagdas; Abhijit R Kulkarni; Nicole A Horenstein
Journal:  Br J Pharmacol       Date:  2017-06-08       Impact factor: 8.739

6.  The nicotinic acetylcholine receptors of zebrafish and an evaluation of pharmacological tools used for their study.

Authors:  Roger L Papke; Fumihito Ono; Clare Stokes; Jason M Urban; R Thomas Boyd
Journal:  Biochem Pharmacol       Date:  2012-05-10       Impact factor: 5.858

7.  Use of an α3β4 nicotinic acetylcholine receptor subunit concatamer to characterize ganglionic receptor subtypes with specific subunit composition reveals species-specific pharmacologic properties.

Authors:  Clare Stokes; Roger L Papke
Journal:  Neuropharmacology       Date:  2012-05-11       Impact factor: 5.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.